List of Nexlizet drug patents
Nexlizet is owned by Esperion Theraps Inc.
Nexlizet contains Bempedoic Acid; Ezetimibe.
Nexlizet has a total of 7 drug patents out of which 0 drug patents have expired.
Nexlizet was authorised for market use on 26 February, 2020.
Nexlizet is available in tablet;oral dosage forms.
Nexlizet can be used as use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease, use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease, a method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe.
Drug patent challenges can be filed against Nexlizet from February, 2024.
The generics of Nexlizet are possible to be released after 14 March, 2036.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7335799 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9000041 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10941095 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10118881 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US8497301 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US9624152 | ESPERION THERAPS INC | Hydroxyl compounds and compositions for cholesterol management and related uses |
Dec, 2023
(10 months from now) | |
| US10912751 | ESPERION THERAPS INC | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease |
Mar, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 21, 2025 |
| New Product (NP) | Feb 26, 2023 |
Drugs and Companies using BEMPEDOIC ACID; EZETIMIBE ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 26 February, 2020
Treatment: Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; Use of nexlizet as an adjunct to diet and maximally tolerated statin therapy for inhibiting cholesterol synthesis to lower ldl-c in adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease; A method of treating heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease by decreasing the level of ldl-c using a fixed dose combination of 180 mg bempedoic acid and 10 mg ezetimibe
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic